Gestational diabetes exhibits lack of carnitine deficiency despite relatively low carnitine levels and alterations in ketogenesis

Author(s): Pappa KI, Anagnou NP, Salamalekis E, Bikouvarakis S, Maropoulos G, et al.

Abstract

Objective: Previous studies have underlined the importance of the carnitine shuttle system and its dysfunction both in normal pregnancy and in type 1 and 2 diabetes. The objective of this paper was to delineate more systematically the role of the carnitine shuttle system in normal pregnancy and in gestational diabetes.

Methods: A total of 119 women matched for age comprised three groups: 40 normal adult non-pregnant women (NNP), 46 normal pregnant women with uncomplicated pregnancy (NP) and 33 women with gestational diabetes (GDM). The latter group was further subdivided into those being managed either by diet alone (25 women, GDM-D) or by insulin (8 women,GDM-I). The following biochemical parameters were assayed: fasting plasma total, free and acyl-carnitine, FFA and beta-OH-butyrate, together with several essential anthropometric parameters.

Results: Women with GDM, in contrast to the control groups, displayed the biochemical features characteristic of insulin resistance: higher body weight, higher BMI, higher skinfold and higher HbAlc levels. No differences on any parameters were found between the two GDM subgroups. Both NP and GDM groups had low levels of total carnitine compared to NNP control group, but surprisingly, the GDM group did not exhibit any further decrease of carnitine levels, as would have been expected by the combination of pregnancy and diabetes. Both groups, despite these low carnitine levels, had no clinical symptoms of carnitine deficiency. Furthermore, the GDM group displayed higher levels of FFA and beta-hydroxybutyrate, which were statistically significant compared to the other two control groups.

Conclusions: The data corroborate the negative effect of normal gestation on the carnitine shuttle system, while they document for the first time that GDM does not further affect the efficiency of the carnitine system. The mild effect of GDMon carnitine status could be explained by the concurrent increased gluconeogenesis, a process which does not affect directly carnitine metabolism.

Similar Articles

Triglyceride metabolism in pregnancy

Author(s): Ghio A, Bertolotto A, Resi V, Volpe L, Di Cianni G

Energy metabolism during human pregnancy

Author(s): Forsum E, Löf M

Clinical and biochemical features of fatty acid oxidation disorders

Author(s): Rinaldo P, Raymond K, al-Odaib A, Bennett MJ

Plasma carnitine levels of pregnant adolescents in labor

Author(s): Koumantakis E, Sifakis S, Koumantaki Y, Hassan E, Matalliotakis I, et al.

Pregnancy-related changes of carnitine and acylcarnitine concentrations of plasma and erythrocytes

Author(s): Schoderbeck M, Auer B, Legenstein E, Genger H, Sevelda P, et al.

Carnitine status and lactate increase in patients with type I juvenile diabetes

Author(s): Evangeliou A, Gourgiotis D, Karagianni C, Markouri M, Anogianaki N, et al.

The effect of the mode of delivery on the maternal-neonatal carnitine blood levels and antioxidant status

Author(s): Schulpis KH, Papakonstantinou ED, Vlachos GD, Vlachos DG, Antsaklis A, et al.

Current understanding of placental fatty acid transport

Author(s): Gil-Sánchez A, Koletzko B, Larqué E

Maternal lipid metabolism and placental lipid transfer

Author(s): Herrera E, Amusquivar E, López-Soldado I, Ortega H

Blood ketone monitoring: a comparison between gestational diabetes and non-diabetic pregnant women

Author(s): Gin H, Vambergue A, Vasseur C, Rigalleau V, Dufour P, et al.

Determination of free L-carnitine levels in type II diabetic women with and without complications

Author(s): Poorabbas A, Fallah F, Bagdadchi J, Mahdavi R, Aliasgarzadeh A, et al.

Oxidative metabolism in insulin-treated gestational diabetes mellitus

Author(s): Hsu HW, Butte NF, Wong WW, Moon JK, Ellis KJ, et al.

Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta

Author(s): Grube M, Meyer Zu Schwabedissen H, Draber K, Präger D, Möritz KU, et al.

High activity of fatty acid oxidation enzymes in human placenta: implications for fetal-maternal disease

Author(s): Oey NA, den Boer ME, Ruiter JP, Wanders RJ, Duran M, et al.

Long-chain fatty acid oxidation during early human development

Author(s): Oey NA, den Boer ME, Wijburg FA, Vekemans M, Augé J, et al.